Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Lancet Neurology

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1474-4422(16)30035-7PMID 27302365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patients and Consumers

  2017cited by this paper
• Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort

  2016cited by this paper
• Compliance to Care Guidelines for Duchenne Muscular Dystrophy

  2015cited by this paper
• Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes

  2015cited by this paper
• 206th ENMC International Workshop: Care for a novel group of patients - adults with Duchenne muscular dystrophy Naarden, The Netherlands, 23-25 May 2014.

  2015cited by this paper
• 206th ENMC International Workshop: Care for a novel group of patients - adults with Duchenne muscular dystrophy

  2015cited by this paper
• Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test

  2015cited by this paper
• The Pathogenesis and Therapy of Muscular Dystrophies.

  2015cited by this paper
• Recent advances in the management of Duchenne muscular dystrophy

  2015cited by this paper
• 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands.

  2015cited by this paper
• Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy

  2015cited by this paper
• Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy.

  2015cited by this paper
• The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials

  2015cited by this paper
• Online Self-Report Data for Duchenne Muscular Dystrophy Confirms Natural History and Can Be Used to Assess for Therapeutic Benefits

  2014cited by this paper
• Dystrophin quantification

  2014cited by this paper
• A Sensitive, Reproducible and Objective Immunofluorescence Analysis Method of Dystrophin in Individual Fibers in Samples from Patients with Duchenne Muscular Dystrophy

  2014cited by this paper
• The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys

  2014cited by this paper
• Adult care for Duchenne muscular dystrophy in the UK

  2014cited by this paper
• One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development.

  2014cited by this paper
• Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy.

  2014cited by this paper
• 6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes

  2014cited by this paper
• Translational and Regulatory Challenges for Exon Skipping Therapies

  2014cited by this paper
• Dystrophin Analysis in Clinical Trials

  2014cited by this paper
• Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression.

  2014cited by this paper
• Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS

  2014cited by this paper
• Biomarkers and surrogate endpoints in Duchenne: meeting report.

  2014cited by this paper
• Antisense-Mediated Exon Skipping: Networking to Meet Opportunities and to Overcome Challenges

  2014cited by this paper
• Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes

  2014cited by this paper
• Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)

  2013cited by this paper
• Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy

  2013cited by this paper
• 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy

  2013cited by this paper
• Magnetic resonance imaging in duchenne muscular dystrophy: Longitudinal assessment of natural history over 18 months

  2013cited by this paper
• Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy

  2013cited by this paper
• THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY

  2013cited by this paper
• Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy

  2013cited by this paper
• Early neurodevelopmental assessment in Duchenne muscular dystrophy.

  2013cited by this paper
• Corticosteroids in Duchenne muscular dystrophy: Major variations in practice

  2013cited by this paper
• The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur

  2013cited by this paper
• The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases

  2013cited by this paper
• Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.

  2013cited by this paper
• International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy

  2012cited by this paper
• Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy.

  2012cited by this paper
• Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens

  2012cited by this paper
• Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients

  2012cited by this paper
• Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

  2012cited by this paper
• Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

  2012cited by this paper
• Evidence‐based path to newborn screening for duchenne muscular dystrophy

  2012cited by this paper
• MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy.

  2012cited by this paper
• Systemic administration of PRO051 in Duchenne's muscular dystrophy.

  2011cited by this paper
• Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

  2011cited by this paper
• The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009.

  2010cited by this paper
• Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

  2010cited by this paper
• Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

  2010cited by this paper
• Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy

  2010cited by this paper
• The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy

  2010cited by this paper
• Collaborating to bring new therapies to the patient--the TREAT-NMD model.

  2009cited by this paper
• Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations.

  2009cited by this paper
• Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations

  2009cited by this paper
• Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

  2009cited by this paper
• Immunohistological intensity measurements as a tool to assess sarcolemma‐associated protein expression

  2009cited by this paper
• Two-tiered hypotheses for Duchenne muscular dystrophy

  2008cited by this paper
• Disability and survival in Duchenne muscular dystrophy

  2008cited by this paper
• Local dystrophin restoration with antisense oligonucleotide PRO051.

  2007cited by this paper
• Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up.

  2007cited by this paper
• Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

  2005cited by this paper
• Dystrophin: the protein product of the Duchene muscular dystrophy locus. 1987.

  1992cited by this paper
• Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

  1987cited by this paper
• This Work Is Licensed under a Creative Commons Attribution 4.0 International License the Treat-nmd Dmd Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations

  year unknowncited by this paper

• Use of Tricyclo-DNA Antisense Oligonucleotides for Exon-Skipping.

  2025cites this paper
• Report of the multistakeholder drug development round table meeting of the World Duchenne Organization focusing on challenges for clinical development of therapies.

  2025cites this paper
• Development of a guideline for orthopaedic management in the care of children and young people with Duchenne muscular dystrophy in the UK National Health Service

  2025cites this paper
• Duchenne Muscular Dystrophy: Clinical Innovations, Ethical Considerations, and Evolving the Path to Adulthood.

  2025cites this paper
• Digital Health for Equitable Rheumatic Care: Integrating Real-World Experiences to Guide Policy Pathways

  2025cites this paper
• A historical perspective on the development of antisense oligonucleotide treatments for Duchenne muscular dystrophy and spinal muscular atrophy

  2025cites this paper
• Indian Rare Disease Stakeholder Mapping

  2024cites this paper
• The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap

  2024cites this paper
• Multiomic characterization of disease progression in mice lacking dystrophin

  2023cites this paper
• Caregiver‐based perception of disease burden in Schaaf‐Yang syndrome

  2023cites this paper
• How to START? Four pillars to optimally begin your orphan drug development

  2023cites this paper
• Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics

  2023cites this paper
• Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers

  2023cites this paper
• Handgrip and finger flexion strength in children: A cross-sectional assessment of age-related normative data and application as a clinical functional marker in paediatric neuromuscular disorders.

  2022cites this paper
• A longitudinal study of creatine kinase and creatinine levels in Duchenne muscular dystrophy

  2022cites this paper
• Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation

  2022cites this paper
• Sarco(endo)plasmic reticulum Ca2+-ATPase function is impaired in skeletal and cardiac muscles from young DBA/2J mdx mice

  2022cites this paper
• Chapter 2 Antisense RNA Therapeutics : A Brief Overview

  2022cites this paper
• THE OFFICIAL JOURNAL OF SOCIETÀ ITALIANA DI FARMACOLOGIA

  2022cites this paper
• Antisense RNA Therapeutics: A Brief Overview.

  2022cites this paper
• Pharmacological inhibition of HDAC6 downregulates TGF-β via Smad2/3 acetylation and improves dystrophin-deficient muscles

  2022cites this paper
• Effects of muscle damage on 31P‐MRS indices of energetic status and sarcolemma integrity in young mdx mice

  2022cites this paper
• Identifying the hub genes for Duchenne muscular dystrophy and Becker muscular dystrophy by weighted correlation network analysis

  2021cites this paper
• SERCA function is impaired in skeletal and cardiac muscles from young DBA/2J mdx mice

  2021cites this paper
• Fondazione Telethon and Unione Italiana Lotta alla Distrofia Muscolare, a successful partnership for neuromuscular healthcare research of value for patients

  2021cites this paper
• The Role of Patient Involvement When Developing Therapies

  2021cites this paper
• Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy

  2021cites this paper
• Quantitative immuno-mass spectrometry imaging of skeletal muscle dystrophin

  2021cites this paper
• Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy

  2021cites this paper
• MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy

  2020cites this paper
• Decision-Making And Selection Bias in Four Observational Studies on Duchenne and Becker Muscular Dystrophy

  2020cites this paper
• Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries

  2020influential citation
• Characterizing Enrollment in Observational Studies of Duchenne Muscular Dystrophy by Race and Ethnicity

  2020cites this paper
• TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy

  2020cites this paper
• Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy

  2020cites this paper
• Quantitative Imaging in Muscle Diseases with Focus on Non-proton MRI and Other Advanced MRI Techniques

  2020cites this paper
• Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle.

  2020cites this paper
• Applications of Fat Mapping

  2020cites this paper
• Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle

  2020cites this paper
• Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks

  2020cites this paper
• EMQN best practice guidelines for genetic testing in dystrophinopathies

  2020cites this paper
• Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers

  2020cites this paper
• Modeling disease trajectory in Duchenne muscular dystrophy

  2020cites this paper
• Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

  2019cites this paper
• Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology

  2019cites this paper
• Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results

  2019cites this paper
• PDGF-BB serum levels are decreased in adult onset Pompe patients

  2019cites this paper
• Exploration of New Contrasts, Targets, and MR Imaging and Spectroscopy Techniques for Neuromuscular Disease – A Workshop Report of Working Group 3 of the Biomedicine and Molecular Biosciences COST Action BM1304 MYO-MRI

  2019cites this paper
• Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy

  2019cites this paper
• What We Have Learned from 10 Years of DMD Exon-Skipping Trials

  2019cites this paper
• Therapeutic developments for Duchenne muscular dystrophy

  2019cites this paper
• Multi‐center evaluation of stability and reproducibility of quantitative MRI measures in healthy calf muscles

  2019cites this paper
• COST Actions: fostering collaborative research for rare diseases.

  2019cites this paper
• Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy

  2019cites this paper
• Mind the gap : Bridging the difference between efficacy and effectiveness of orphan drugs

  2018cites this paper
• Meeting report of the "Regulatory Exchange Matters" session at the 5th International TREAT-NMD Conference:: Lessons in communication: How an early dialogue between patients, regulators and academics can further therapy development for neuromuscular disorders Freiburg, Germany, 27-29 November 2017.

  2018cites this paper
• Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy

  2018cites this paper
• Use of Tricyclo-DNA Antisense Oligonucleotides for Exon Skipping.

  2018cites this paper
• A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples

  2018cites this paper
• Report on the workshop: Meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30-31 January 2017.

  2018cites this paper
• Biomarkers of Duchenne muscular dystrophy: current findings

  2018cites this paper
• Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study

  2018cites this paper
• Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials

  2018cites this paper
• 226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands.

  2018influential citation
• Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy.

  2018cites this paper
• Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands

  2018cites this paper
• Splice-Switching Oligonucleotides

  2018cites this paper
• FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

  2017cites this paper
• Eteplirsen in the treatment of Duchenne muscular dystrophy

  2017cites this paper
• Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy.

  2017cites this paper
• Stakeholder collaboration for spinal muscular atrophy therapy development.

  2017cites this paper
• [Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].

  2017cites this paper
• Dystrophinopathies and Limb-Girdle Muscular Dystrophies

  2017cites this paper
• Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24–month follow-up

  2017cites this paper
• GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells

  2017cites this paper
• Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases

  2017cites this paper
• Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease

  2017cites this paper
• Reference values for developing responsive functional outcome measures across the lifespan

  2017cites this paper
• Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD)

  2017cites this paper
• Delivery is key: lessons learnt from developing splice‐switching antisense therapies

  2017cites this paper
• Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model

  2017cites this paper
• Treatment of Duchenne muscular dystrophy: first small steps.

  2017cites this paper
• Exon skipping: a first in class strategy for Duchenne muscular dystrophy

  2017cites this paper
• Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues

  2017cites this paper
• The golden retriever model of Duchenne muscular dystrophy

  2017cites this paper
• Translational development of splice-modifying antisense oligomers

  2017cites this paper
• Duchenne muscular dystrophy: meeting the therapeutic challenge.

  2016cites this paper
• 1000 NORMS PROJECT: MEASURES OF PHYSICAL FUNCTION ACROSS THE LIFESPAN

  2016cites this paper